Welcome to our dedicated page for FILANA THERAPEUTICS SEC filings (Ticker: SAVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FILANA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FILANA THERAPEUTICS's regulatory disclosures and financial reporting.
Cassava Sciences expanded its Board of Directors to eight members and appointed Dawn Carter Bir as a Class I director, effective October 21, 2025. Her term will expire at the Company’s 2028 annual meeting of stockholders.
The Company stated there are no arrangements or understandings behind the appointment and no related‑party transactions requiring disclosure. Ms. Bir was made eligible for compensation under the Non‑employee Director Compensation Program and signed the Company’s standard indemnification agreement. A press release announcing the appointment was furnished as Exhibit 99.1.
Robert Christopher Cook, listed as Chief Operating & Legal Officer and a director of Cassava Sciences, Inc. (SAVA), reported an insider purchase on 09/30/2025. The Form 4 shows an acquisition of 13,725 shares of common stock at a price of $2.91 per share, and the filing reports 13,725 shares beneficially owned following the transaction. The report was signed under power of attorney on 10/02/2025.
Cassava Sciences insider purchase by CEO and director. Barry Richard, serving as President & CEO and a director, reported open-market purchases of 7,172 shares of Cassava Sciences Inc. (SAVA) on 09/22/2025 at a weighted average price of $2.28 per share (individual trades ranged $2.27–$2.29). After the transactions the reporting person beneficially owns 714,675 shares indirectly through a trust. The Form 4 was signed by power of attorney on 09/23/2025.
Cassava Sciences (SAVA) Director and President & CEO Barry Richard reported multiple open-market purchases of the company's common stock on September 18-19, 2025, acquiring a total of 237,941 shares at prices between $2.13 and $2.29. Following these transactions he beneficially owned 707,503 shares, held indirectly through a trust. The Form 4 was signed by an authorized POA on September 22, 2025.
Cassava Sciences, Inc. filed a current report to furnish its latest corporate presentation under Regulation FD. The presentation, dated September 2025, is made available as Exhibit 99.1 and is also posted in the Investors section of the company’s website. The company states that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and will not be automatically incorporated into other securities law filings.
Cassava Sciences reported a net loss of $44.2 million for the quarter and $67.6 million for the six months ended June 30, 2025, driven by $40.3 million of general and administrative expense and $5.1 million of research and development expense in the quarter. Cash and cash equivalents totaled $112.4 million, down from $128.6 million at year-end 2024, while total assets fell to $135.4 million and stockholders' equity declined to $88.0 million. Accounts payable and accrued expenses increased materially to $42.8 million, contributing to total liabilities of $47.4 million.
The company recorded $35.25 million of litigation loss contingencies as of June 30, 2025, including a $31.25 million reserve related to the consolidated securities action and a $4.0 million reserve related to an anti-SLAPP matter. Cassava paid a $40 million civil penalty to settle an SEC enforcement matter in 2024 and continues to cooperate with DOJ inquiries. Management states working capital is sufficient for at least the next 12 months. Operationally, the company completed the phase-out of its Alzheimer’s program in Q2 2025, entered a Yale license for simufilam in TSC-related epilepsy with up to $4.5 million in milestones plus tiered royalties, and announced positive preclinical TSC results showing a dose-related reduction in seizures in a mouse model.
Cassava Sciences, Inc. furnished an 8-K related to its results of operations and financial condition. On August 14, 2025, the company issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The press release contains the detailed financial and operating information.
The company specifies that the information in this report, including Exhibit 99.1, is being furnished and not filed under the Securities Exchange Act of 1934, which limits its use for certain legal liability purposes and for incorporation by reference into other securities filings.
Cassava Sciences (SAVA) filed an 8-K to disclose positive preclinical data for simufilam in tuberous sclerosis complex (TSC)-related epilepsy. In a Tsc1 conditional knockout mouse model that develops spontaneous seizures, multiple doses of simufilam were tested over ~3 weeks. The compound significantly reduced seizure progression in a dose-dependent manner; other measured endpoints did not reach significance.
The study was run with the TSC Alliance and PsychoGenics under the TSC Preclinical Consortium. Management plans to present full data at a scientific meeting and initiate the first human proof-of-concept trial in H1 2026. No financial terms, revenue impact, or guidance were provided. Item 7.01 makes the accompanying press release furnished, not filed.
Key takeaways:
- Preclinical efficacy signal supports simufilam’s mechanism beyond Alzheimer’s.
- Expands pipeline into rare-disease epilepsy market.
- Tight timeline sets a near-term catalyst but still carries high development risk.